Cargando…

Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas

BACKGROUND: Central nervous system lymphomas (CNSL) is a devastating disease. Currently, a confirmatory biopsy is required prior to treatment. OBJECTIVE: Our investigation aims to prove the feasibility of a minimally-invasive diagnostic approach for the molecular characterization of CNSL. METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Hickmann, Anne-Katrin, Frick, Maximilian, Hadaschik, Dirk, Battke, Florian, Bittl, Markus, Ganslandt, Oliver, Biskup, Saskia, Döcker, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397454/
https://www.ncbi.nlm.nih.gov/pubmed/30823914
http://dx.doi.org/10.1186/s12885-019-5394-x
_version_ 1783399418783858688
author Hickmann, Anne-Katrin
Frick, Maximilian
Hadaschik, Dirk
Battke, Florian
Bittl, Markus
Ganslandt, Oliver
Biskup, Saskia
Döcker, Dennis
author_facet Hickmann, Anne-Katrin
Frick, Maximilian
Hadaschik, Dirk
Battke, Florian
Bittl, Markus
Ganslandt, Oliver
Biskup, Saskia
Döcker, Dennis
author_sort Hickmann, Anne-Katrin
collection PubMed
description BACKGROUND: Central nervous system lymphomas (CNSL) is a devastating disease. Currently, a confirmatory biopsy is required prior to treatment. OBJECTIVE: Our investigation aims to prove the feasibility of a minimally-invasive diagnostic approach for the molecular characterization of CNSL. METHODS: Tissue biopsies from 6 patients with suspected CNSL were analyzed using a 649gene next-generation sequencing (NGS) tumor panel (tumor vs. reference tissue (EDTA-blood)). The individual somatic mutation pattern was used as a basis for the digital PCR analyzing circulating tumor DNA (ctDNA) from plasma and cerebrospinal fluid (CSF) samples, identifying one selected tumor mutation during this first step of the feasibility investigation. RESULTS: NGS-analysis of biopsy tissue revealed a specific somatic mutation pattern in all confirmed lymphoma samples (n = 5, NGS-sensitivity 100%) and none in the sample identified as normal brain tissue (NGS-specificity 100%). cfDNA-extraction was dependent on the extraction-kit used and feasible in 3 samples, in all of which somatic mutations were detectable (100%). Analysis of CSF-derived cfDNA was superior to plasma-derived cfDNA and routine microscopic analysis (lymphoma cells: n = 2, 40%). One patient showed a divergent molecular pattern, typical of Burkitt-Lymphoma (HIV+, serologic evidence of EBV-infection). Lumbar puncture was tolerated without complications, whereas biopsy caused 3 hemorrhages. CONCLUSIONS: Our investigation provides evidence that analysis of cfDNA in central nervous system tumors is feasible using the described protocol. Molecular characterization of CNSL could be achieved by analysis of CSF-derived cfDNA. Knowledge of a tumor’s specific mutation pattern may allow initiation of targeted therapies, treatment surveillance and could lead to minimally-invasive diagnostics in the future. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5394-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6397454
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63974542019-03-13 Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas Hickmann, Anne-Katrin Frick, Maximilian Hadaschik, Dirk Battke, Florian Bittl, Markus Ganslandt, Oliver Biskup, Saskia Döcker, Dennis BMC Cancer Case Report BACKGROUND: Central nervous system lymphomas (CNSL) is a devastating disease. Currently, a confirmatory biopsy is required prior to treatment. OBJECTIVE: Our investigation aims to prove the feasibility of a minimally-invasive diagnostic approach for the molecular characterization of CNSL. METHODS: Tissue biopsies from 6 patients with suspected CNSL were analyzed using a 649gene next-generation sequencing (NGS) tumor panel (tumor vs. reference tissue (EDTA-blood)). The individual somatic mutation pattern was used as a basis for the digital PCR analyzing circulating tumor DNA (ctDNA) from plasma and cerebrospinal fluid (CSF) samples, identifying one selected tumor mutation during this first step of the feasibility investigation. RESULTS: NGS-analysis of biopsy tissue revealed a specific somatic mutation pattern in all confirmed lymphoma samples (n = 5, NGS-sensitivity 100%) and none in the sample identified as normal brain tissue (NGS-specificity 100%). cfDNA-extraction was dependent on the extraction-kit used and feasible in 3 samples, in all of which somatic mutations were detectable (100%). Analysis of CSF-derived cfDNA was superior to plasma-derived cfDNA and routine microscopic analysis (lymphoma cells: n = 2, 40%). One patient showed a divergent molecular pattern, typical of Burkitt-Lymphoma (HIV+, serologic evidence of EBV-infection). Lumbar puncture was tolerated without complications, whereas biopsy caused 3 hemorrhages. CONCLUSIONS: Our investigation provides evidence that analysis of cfDNA in central nervous system tumors is feasible using the described protocol. Molecular characterization of CNSL could be achieved by analysis of CSF-derived cfDNA. Knowledge of a tumor’s specific mutation pattern may allow initiation of targeted therapies, treatment surveillance and could lead to minimally-invasive diagnostics in the future. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5394-x) contains supplementary material, which is available to authorized users. BioMed Central 2019-03-01 /pmc/articles/PMC6397454/ /pubmed/30823914 http://dx.doi.org/10.1186/s12885-019-5394-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Hickmann, Anne-Katrin
Frick, Maximilian
Hadaschik, Dirk
Battke, Florian
Bittl, Markus
Ganslandt, Oliver
Biskup, Saskia
Döcker, Dennis
Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas
title Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas
title_full Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas
title_fullStr Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas
title_full_unstemmed Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas
title_short Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas
title_sort molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor dna in patients with central nervous system lymphomas
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397454/
https://www.ncbi.nlm.nih.gov/pubmed/30823914
http://dx.doi.org/10.1186/s12885-019-5394-x
work_keys_str_mv AT hickmannannekatrin moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas
AT frickmaximilian moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas
AT hadaschikdirk moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas
AT battkeflorian moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas
AT bittlmarkus moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas
AT ganslandtoliver moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas
AT biskupsaskia moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas
AT dockerdennis moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas